First clinical results for PSMA targeted alpha therapy using ²²⁵Ac-PSMA-I&T in advanced metastatic castration resistant prostate cancer patients: promising antitumor effect in advanced mCRPC even after failure of prior ¹⁷⁷Lu-PSMA treatment with tolerable side effects. Read more>>